Rofleponide 21-palmitate
Rofleponide 21-palmitate is a lipophilic Corticosteroid prodrug. Rofleponide 21-palmitate reduces subcutaneous edema, plasma haptoglobin levels, and plasma levels of IL-6, KC, IP-10, MCP-1. Rofleponide 21-palmitate increases and prolongs mRNA-encoded protein expression in lipid nanoparticle formulations.
For research use only. We do not sell to patients.
- CAS No.: 144653-57-6
- Formula: C41H64F2O7
- Molecular Weight:706.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vivo
Rofleponide 21-palmitate (Rofleponide 21-palmitate:mRNA weight ratio 1:1; fixed mRNA dose 0.3 mg/kg; s.c.; single dose) in DLin-MC3-DMA-based LNPs eliminates LNP-induced edema, reduces plasma haptoglobin levels, prolongs mRNA 1 protein expression in mice[1].
Rofleponide 21-palmitate (Rofleponide 21-palmitate:mRNA weight ratio 1:1; fixed mRNA dose 0.3 mg/kg; s.c.; single dose) in Merck-32-based LNPs significantly reduces LNP-induced edema and plasma haptoglobin levels while increasing mRNA 1 protein expression in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Crl:Cd1(ICR) mice (female, ~12 weeks old)[1]
-
Dosage:Rofleponide 21-palmitate:mRNA weight ratios of 1:1, 1:10, 1:30; fixed mRNA dose of 0.3 mg/kg
-
Administration:s.c.; single dose
-
Result:Significantly reduced edema scoring across all rofleponide 21-palmitate LNP groups compared to non-anti-inflammatory LNPs at 24 hours post-administration.
Significantly reduced plasma haptoglobin levels across all ratios compared to non-anti-inflammatory LNPs at 24 hours post-administration.
Increased and prolonged mRNA 1 protein expression over 0-24 hours compared to non-anti-inflammatory LNPs.
-
Animal Model:Crl:Cd1(ICR) mice (female, ~12 weeks old)[1]
-
Dosage:Rofleponide 21-palmitate:mRNA weight ratio of 1:1; fixed mRNA dose of 0.3 mg/kg
-
Administration:s.c.; single dose
-
Result:Achieved edema scoring of 0 at 24, 48, and 72 hours post-administration, compared to a score of 5 for rofleponide-containing LNPs at the same molar dose.
Significantly lowered plasma haptoglobin levels at 25, 50, and 75 hours post-administration compared to rofleponide-containing LNPs.
Increased and prolonged mRNA 1 protein expression.
Reached a rofleponide plasma concentration peak of ~6 nM at 2.5 hours post-administration, with a gradual decline over 24 hours, while Rofleponide-containing LNPs showed an initial peak of ~75 nM followed by a rapid drop to near 0 by 5 hours.\n
Reduced edema scoring at 24 hours post-administration compared to non-anti-inflammatory Merck-32 LNPs.
Significantly reduced plasma haptoglobin levels at 24 hours post-administration compared to non-anti-inflammatory Merck-32 LNPs.
Increased mRNA 1 protein expression over 0-24 hours.
-
Animal Model:Crl:Cd1(ICR) mice (female, ~12 weeks old)[1]
-
Dosage:Rofleponide 21-palmitate:mRNA weight ratio of ~1:1; fixed mRNA dose of 0.3 mg/kg
-
Administration:s.c.; single dose
-
Result:Reduced edema scoring to near 0 at 24 hours post-administration.
Significantly reduced plasma haptoglobin levels at 24 hours post-administration compared to non-anti-inflammatory LNPs.
Increased and prolonged mRNA 1 protein expression over 0-24 hours, reaching ~0.8 ng/mL at 24 hours compared to near 0 ng/mL for non-anti-inflammatory LNPs.
Chemical Information
-
CAS No. 144653-57-6
-
Molecular Weight 706.94
-
Formula C41H64F2O7
-
SMILES
CCCCCCCCCCCCCCCC(OCC([C@]12[C@@]3([C@@]([C@@]4([H])[C@]([C@H](C3)O)([C@@]5(C([C@H](C4)F)=CC(CC5)=O)C)F)([H])C[C@@]1([H])O[C@H](O2)CCC)C)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)